Skip to main content

Table 3 Non randomized clinical trials of HCC treatment with SA monotherapy

From: The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Publication

Type of study

Number of enrolled patients and controls

Type of Cancer

SA used for treatment

Response to treatment-outcome

  

Patients

Controls

   

Dimitroulopoulos 2002[211]

NRCT

15*

13#

Advanced HCC

OCT LAR (20 to 30 mg/28d)

↑S, ↑QoL

Gill 2005[212]

NRCT

22*

20#

Advanced HCC

OCT LAR (20 mg/28d)

↑S, ↑QoL, ↓AFP, PR

Samonakis 2002[213]

NRCT

32*

27#

Advanced HCC

NS

↑S, ↑QoL,

Plentz 2005[214]

NRCT

41*

33â–ª

Advanced HCC

OCT LAR (30 mg/28d)

=S

Schoniger-Hekele 2009[215]

NRCT

25*

39†

Advanced HCC

OCT LAR (30 mg/28d)

↑S

  

or 17â–ª

    
  

or 17â–«

    

Slijkhuis 2005[216]

NRCT

30*

-

Advanced HCC

OCT LAR (30 mg/28d)

SD

  1. NRCT, Non randomized clinical trial.
  2. AFP, Alpha fetoprotein.
  3. S, Survival.
  4. TACE, Transarterial chemoembolization.
  5. PR, Partial response.
  6. SD, Stable disease.
  7. NS, Not specified.
  8. QoL, Quality of life.
  9. *: treated patients.
  10. #: untreated patients.
  11. â–ª: TACE treatment.
  12. â–«: multimodal therapy.
  13. †: palliative.
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us